1. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. The 304 Study Group;Nabholtz;J Clin Oncol,1999
2. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group;Chan;J Clin Oncol,1999
3. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC;Nabholtz;Proc Am Soc Clin Oncol,1999
4. A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (Pts) with metastatic breast cancer (MBC);Nabholtz;Proc Am Soc Clin Oncol,2001
5. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients;Aas;Nat Med,1996